Shares of clinical-stage biotechnology company Recursion Pharmaceuticals (NASDAQ: RXRX) soared 11.43% on Wednesday, significantly outperforming the broader market. The rally followed a major analyst upgrade and positive clinical trial news, underscoring growing investor confidence in the company’s AI-powered drug discovery platform—a platform that previously attracted a strategic investment from tech giant Nvidia.
Prior to the market open, J.P. Morgan analyst Priyanka Grover upgraded Recursion’s rating from Neutral to Overweight (equivalent to a “Buy” recommendation). Grover also raised her price target on the stock by 10% to $11 per share.
The upgrade was largely driven by encouraging clinical trial results for Recursion’s investigational drug REC-4881, designed to treat familial adenomatous polyposis (FAP). Data from a Phase 1b/2 trial demonstrated the drug’s efficacy, leading the analyst to highlight its blockbuster potential—with future annual sales possibly exceeding $1 billion. Grover estimates a 60% probability of the drug successfully reaching the market.
Beyond the specific drug candidate, market attention remains focused on Recursion’s proprietary AI-driven drug discovery platform, Recursion OS. This technology was key to securing a $50 million strategic investment from Nvidia in July 2023—an announcement that had previously propelled Recursion’s stock approximately 80% higher in a single day.
The two companies are collaborating to train and scale Recursion’s AI models on Nvidia’s cloud platform, with plans to integrate them into BioNeMo, Nvidia’s generative AI platform for drug discovery. The partnership positions Recursion as an important player in Nvidia’s expanding healthcare and life sciences ecosystem, with potential for deeper collaboration as pipeline assets advance.
While the recent developments are positive, investors are reminded that drug development carries substantial risk. Clinical-stage candidates, including REC-4881, may fail to gain regulatory approval despite promising early data. As with many biotechnology investments, high potential is accompanied by high uncertainty, even with strong technological backing and strategic partnerships.
